



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## Ascrinvacumab

Cat. No.:	HY-P99353
CAS No.:	1463459-96-2
Target:	Anaplastic lymphoma kinase (ALK)
Pathway:	Protein Tyrosine Kinase/RTK
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

### BIOLOGICAL ACTIVITY

<b>Description</b>	Ascrinvacumab (PF-03446962) is a human IgG2 monoclonal antibody targets ALK-1. Ascrinvacumab shows binding efficiency with human ALK1 with a $K_d$ value of 7 nM. Ascrinvacumab can be used for the research of hepatocellular carcinoma (HCC) <sup>[1]</sup> .
<b>In Vitro</b>	Ascrinvacumab binds to cellular human ALK1 with a $K_d$ value of 7 nm <sup>[1]</sup> . Ascrinvacumab (30 min) blocks bone morphogenetic protein 9 (BMP9)- and fetal calf serum (FCS)-induced responses and mitigates BMP9-induced intensity and duration of Smad1 phosphorylation <sup>[1]</sup> . Ascrinvacumab (0.01-10 µg/mL; 2 h) inhibits BMP9 binding to ALK1 <sup>[1]</sup> . Ascrinvacumab (40 µg/mL; 2 h) potentially inhibits endothelial sprouting in human umbilical vein endothelial cells (HUVECs) <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
<b>In Vivo</b>	Ascrinvacumab decreases human vessel density and improves antitumor efficacy when combined with bevacizumab (anti-VEGF) in mouse chimera tumor model <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

[1]. van Meeteren LA, et al. Anti-human activin receptor-like kinase 1 (ALK1) antibody attenuates bone morphogenetic protein 9 (BMP9)-induced ALK1 signaling and interferes with endothelial cell sprouting. J Biol Chem. 2012 May 25;287(22):18551-61.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA